Artwork

A tartalmat a NFX biztosítja. Az összes podcast-tartalmat, beleértve az epizódokat, grafikákat és podcast-leírásokat, közvetlenül a NFX vagy a podcast platform partnere tölti fel és biztosítja. Ha úgy gondolja, hogy valaki az Ön engedélye nélkül használja fel a szerzői joggal védett művét, kövesse az itt leírt folyamatot https://hu.player.fm/legal.
Player FM - Podcast alkalmazás
Lépjen offline állapotba az Player FM alkalmazással!

NFXBio: TechBio Platforms Developing a Universal Vaccine & Beating Treatment-Resistant Cancer

51:52
 
Megosztás
 

Manage episode 347786743 series 2528675
A tartalmat a NFX biztosítja. Az összes podcast-tartalmat, beleértve az epizódokat, grafikákat és podcast-leírásokat, közvetlenül a NFX vagy a podcast platform partnere tölti fel és biztosítja. Ha úgy gondolja, hogy valaki az Ön engedélye nélkül használja fel a szerzői joggal védett művét, kövesse az itt leírt folyamatot https://hu.player.fm/legal.
In this episode, Nick Goldner and Jacob Glanville share their founder journeys and discuss platform technologies in biotech. They delve into the business models of Resistance Bio and Sentivax, strategies for infectious diseases, and the challenges of scientific entrepreneurship. The conversation shifts to fundraising experiences and understanding investor feedback, concluding with visions for the future of biotech.

In biology we have a saying: what doesn’t kill you mutates and tries again.

Cancer. Deadly viruses. These problems are so hard to tackle because the goalposts are always moving. Thanks to evolution, these diseases often outpace therapies and vaccines.

Today, NFX General Partner and Head of NFX Bio Omri Amirav-Drory is sitting down with two Founders using platforms to stay a step ahead of evolution. Jacob Glanville, Founder of Centivax, has developed a platform to create broad spectrum vaccines capable of arming the immune system against rapidly mutating viruses (like COVID-19 or influenza). Nick Goldner, Founder of resistanceBio, discusses his approach for mapping all the possible resistance paths a cancer can take in the human body – and developing therapies to shut those escape routes down.

Here’s why we need platforms to tackle biology’s biggest problems, what it takes to build a platform company, and their advice for fundraising in Techbio.

(0:00) Introduction to the episode and guests (1:45) Founders' journeys: Nick Goldner and Jacob Glanville (8:19) Discussion on platform technologies in biotech (23:30) In-depth look at Resistance Bio and Sentivax's platforms and business models (28:45) Strategies for addressing infectious diseases (34:15) Overcoming challenges in scientific entrepreneurship (34:59) Transition to discussing fundraising experiences (43:42) Understanding the investor's perspective and adapting based on feedback (47:34) Vision for the future of their platforms and the intersection of biology and technology (51:33) Outro and podcast reminders
  continue reading

171 epizódok

Artwork
iconMegosztás
 
Manage episode 347786743 series 2528675
A tartalmat a NFX biztosítja. Az összes podcast-tartalmat, beleértve az epizódokat, grafikákat és podcast-leírásokat, közvetlenül a NFX vagy a podcast platform partnere tölti fel és biztosítja. Ha úgy gondolja, hogy valaki az Ön engedélye nélkül használja fel a szerzői joggal védett művét, kövesse az itt leírt folyamatot https://hu.player.fm/legal.
In this episode, Nick Goldner and Jacob Glanville share their founder journeys and discuss platform technologies in biotech. They delve into the business models of Resistance Bio and Sentivax, strategies for infectious diseases, and the challenges of scientific entrepreneurship. The conversation shifts to fundraising experiences and understanding investor feedback, concluding with visions for the future of biotech.

In biology we have a saying: what doesn’t kill you mutates and tries again.

Cancer. Deadly viruses. These problems are so hard to tackle because the goalposts are always moving. Thanks to evolution, these diseases often outpace therapies and vaccines.

Today, NFX General Partner and Head of NFX Bio Omri Amirav-Drory is sitting down with two Founders using platforms to stay a step ahead of evolution. Jacob Glanville, Founder of Centivax, has developed a platform to create broad spectrum vaccines capable of arming the immune system against rapidly mutating viruses (like COVID-19 or influenza). Nick Goldner, Founder of resistanceBio, discusses his approach for mapping all the possible resistance paths a cancer can take in the human body – and developing therapies to shut those escape routes down.

Here’s why we need platforms to tackle biology’s biggest problems, what it takes to build a platform company, and their advice for fundraising in Techbio.

(0:00) Introduction to the episode and guests (1:45) Founders' journeys: Nick Goldner and Jacob Glanville (8:19) Discussion on platform technologies in biotech (23:30) In-depth look at Resistance Bio and Sentivax's platforms and business models (28:45) Strategies for addressing infectious diseases (34:15) Overcoming challenges in scientific entrepreneurship (34:59) Transition to discussing fundraising experiences (43:42) Understanding the investor's perspective and adapting based on feedback (47:34) Vision for the future of their platforms and the intersection of biology and technology (51:33) Outro and podcast reminders
  continue reading

171 epizódok

Minden epizód

×
 
Loading …

Üdvözlünk a Player FM-nél!

A Player FM lejátszó az internetet böngészi a kiváló minőségű podcastok után, hogy ön élvezhesse azokat. Ez a legjobb podcast-alkalmazás, Androidon, iPhone-on és a weben is működik. Jelentkezzen be az feliratkozások szinkronizálásához az eszközök között.

 

Gyors referencia kézikönyv